NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

September 26, 2020

Study Completion Date

July 31, 2024

Conditions

Adult Burkitt LymphomaB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt LymphomaDiffuse Large B-Cell LymphomaMYC Gene MutationPlasmablastic Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IT or intraventricularly

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Methotrexate

Given IT or intraventricularly

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Therapeutic Hydrocortisone

Given IT or intraventricularly

DRUG

Vincristine Sulfate

Given IV

Trial Locations (5)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

02155

Tufts University, Medford

08901

Rutgers Cancer Institute of New Jersey, New Brunswick